Description
Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a agent-linker conjugate for ADC.–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Cancer-programmed cell death-Formula-C70H104N12O14S-Citation–References-[1]Antibody-drug conjugates Patent: WO 2013068874 A1-CASNumber-1401963-17-4-MolecularWeight-1369.71-Compound Purity-99.96-SMILES-O=C1N(CCCCCC(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC2=CC=C(COC(N([C@@H](C(C)C)C(N[C@@H](C(C)C)C(N([C@H]([C@@H](CC(N3[C@@H](CCC3)[C@H](OC)[C@H](C(N[C@H](C4=NC=CS4)CC5=CC=CC=C5)=O)C)=O)OC)[C@@H](C)CC)C)=O)=O)C)=O)C=C2)=O)=O)=O)C(C=C1)=O-Research_Area-Cancer-Solubility-DMSO : ≥ 160 mg/mL-Target-Drug-Linker Conjugates for ADC;Microtubule/Tubulin-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related
